grant
Validation of an aqueous humor liquid biopsy for molecular prognostication and monitoring of children with retinoblastoma.
Organization CHILDREN'S HOSPITAL OF LOS ANGELESLocation LOS ANGELES, UNITED STATESPosted 1 Aug 2023Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY20250-11 years oldAbscissionAffectAgeAnti-OncogenesAntioncogenesAqueous HumorArteriesAssayAwardBehaviorBioassayBiological AssayBiological MarkersBiopsyBlindnessCancer Suppressor GenesCancersChildChild YouthChildhoodChildren (0-21)ClinicalClinical TrialsCollaborationsCommunicationDNA AlterationDNA MethylationDNA Sequence AlterationDNA methylation profilingDNA mutationDetectionDiagnosisDiseaseDisorderEarly DiagnosisEmerogenesEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEvaluationExcisionExtirpationEyeEye CancerEye EnucleationEyeballFutureGeneral Prognostic FactorGeneticGenetic AlterationGenetic ChangeGenetic defectGenetic mutationGenomicsGoalsGroupingInjectionsIntraocular FluidKnowledgeLaboratoriesLogistic RegressionsMYCNMYCN geneMalignant Eye NeoplasmMalignant NeoplasmsMalignant Ocular NeoplasmMalignant Ocular TumorMalignant TumorMalignant Tumor of the EyeMeasuresMethyl-SeqMethylSeqMethylationMethylation sequencingModalityModelingModificationMolecularMonitorMutationNMYCNMYC GeneNatureNorth AmericaOnco-Suppressor GenesOncogenes-Tumor SuppressorsOncogenesisOperative ProceduresOperative Surgical ProceduresOutcomePathogenicityPatientsPositionPositioning AttributePrediction of Response to TherapyPrognosisPrognostic FactorPrognostic MarkerPrognostic/Survival FactorProspective StudiesRB1RB1 geneRecessive OncogenesRecurrenceRecurrentRelapseRemovalResearchResearch SpecimenResidualResidual stateRetinaRetinal NeuroblastomaRetinoblastomaRiskRisk MarkerSamplingSequence AlterationSourceSpecimenSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalTM-MKRTestingTimeTreatment FailureTreatment outcomeTumor MarkersTumor SubtypeTumor Suppressing GenesTumor Suppressor GenesTumor TissueTumor-DerivedValidationVariantVariationagesbio-markersbiologic markerbiomarkerbiomarker identificationbiomarker validationcancer biomarkerscancer markerscancer riskcandidate biomarkercandidate markercell free DNAcell free circulating DNAchemotherapychromosome 6p gainclinical examclinical examinationclinical relevanceclinically relevantcopy number alterationdesigndesigningdisease diagnosisdisease prognosisdisease prognosticationearly detectionentire genomeepigeneticallyepigenomicsexpression subtypesfull genomegenome mutationgenome scalegenome sequencinggenome-widegenomewidegenomic alterationgenomic biomarkergenomic markergroupingshigh riskidentification of biomarkersidentification of new biomarkersin vivokidsliquid biopsymalignancymalignant neoplasm of eyemarker identificationmarker validationmolecular diagnosticsmolecular sub-typesmolecular subsetsmolecular subtypesmulti-modalitymultimodalitymultiomicsmultiple omicsneoplasm/cancernoveloncosuppressor genepanomicsparticipant enrollmentpatient enrollmentpediatricpersonalization of treatmentpersonalized medicinepersonalized therapypersonalized treatmentprecision medicineprecision medicine clinical trialsprecision-based medicinepredict therapeutic responsepredict therapy responseprognosticprognostic biomarkerprognostic indicatorprognosticationprospectiverelapse riskresectionresponse to therapyresponse to treatmentretina neuroblastomaretinoblastoma-1risk predictorrisk predictorssurgerytargeted sequencingtherapeutic responsetherapeutic targettherapy failuretherapy predictiontherapy responsetreatment predictiontreatment responsetreatment response predictiontreatment responsivenesstreatment risktumortumor DNAtumor behaviortumor biomarkertumor cell DNAtumor specific biomarkertumor-specific DNAtumorigenesisvalidationsvision lossvisual losswhole genomeyoungster
Description preview
Project Summary
There is a significant body of research into the genetic, genomic and epigenomic alterations of retinoblastoma
(RB), a primary eye cancer that forms in the developing retina in young children. However, these studies were
done on tumor tissues from surgically removed (enucleated) eyes with advanced RB, as tumor biopsy is not…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click